Publications
506 publications
- Date
- Relevance
-
Organisation chart 2025
This document gives an overview of the members of the Executive Board (RvB), the management of the National Health Care Institute ...
-
Multi-year research agenda
The multi-year research agenda of the National Health Care Institute provides direction on what we research. Our research ...
-
Advice - reimburse lisocabtagene maraleucel (Breyanzi®) for the treatment of lymphoma
The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse lisocabtagene ...
-
Report - Cost-effectiveness: recommendations for surrogate endpoints
The National Health Care Institute and similar government organisations in England, Canada, the United States, Colombia and ...
-
Advice - reimburse atogepant (Aquipta®) for the treatment of migraine
The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse atogepant (Aquipta®) ...
-
Advice - do not reimburse olaparib (Lynparza®) in combination with abiraterone for the treatment of metastatic prostate cancer
The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to not reimburse olaparib ...
-
Advice - do not reimburse 9vHPV vaccine (Gardasil 9®) against cancer due to HPV virus for certain women
The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) not to reimburse 9vHPV vaccine ...
-
Taking care of good healthcare
-
Advice - reimburse fluorouracil cream (Tolak®) for the treatment of the skin condition actinic keratosis
The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse 5-fluorouracil 4% ...
-
Advice - reimburse mometasone/olopatadine nasal spray (Ryaltris®) for the treatment of allergic rhinitis
The National Health Care Institute has advised the minister of Health, Welfare and Sport to reimburse mometasone/olopatadine ...